Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 327 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Sound Waves Can Target Lymph Nodes And Help Kill Breast Cancer... November 22, 2019 What can elephants teach us about cancer? August 12, 2023 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 Texting May Help Reduce Disparities in Colorectal Cancer Screening March 19, 2021 Load more HOT NEWS NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... Scientists reveal how air pollution can cause lung cancer in people... Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas Smoking Initiation Shifting from Teens to Young Adults
